

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that, based on the results of the quarterly review of the Hang Seng Family of Indexes announced by Hang Seng Indexes Company Limited on 16 February 2024, the Company has been selected and will be included as a constituent stock of the following index series, with effect from 4 March 2024:

1. Hang Seng Small Cap (Investable) Index;
2. Hang Seng Stock Connect Hong Kong Index;
3. Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index;
4. Hang Seng Stock Connect Hong Kong SmallCap Index; and
5. Hang Seng SCHK Mainland China Companies Index.

The Board believes that the Company’s inclusion as a constituent stock of the above index series represents market recognition of the Group’s business performance and development prospects, and is expected to further facilitate the expansion of the Company’s shareholder base and increase trading liquidity of the shares of the Company.

The Board would like to thank the shareholders and investors of the Company for their continuous support. The Company will continue to actively seek market opportunities, strive to develop its business and create value for its shareholders.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 20 February 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.